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Abstract
Introduction. Lymphatic invasion (LYI) and lymphangiogenesis in the primary tumor are important processes 
related to the dissemination of neoplasms. The aim of the study was to examine the relationship of LYI status 
in cutaneous melanoma with patient survival and clinicopathological data.
Material and methods. LYI status was assessed in 104 hematoxylin-eosin (H&E) stained melanoma primary 
tumor samples and analyzed in relation to patient survival and other clinicopathological and histopathological 
characteristics. 
Results. LYI was found in 30 (28.8%) patients. It was observed more frequently in ulcerated, proliferating, 
and thicker tumors. It correlated with the presence of sentinel lymph node, regional and distant metastases. 
The presence of LYI significantly correlated with shorter overall survival, cancer specific overall survival and 
disease-free survival in Kaplan-Meier analysis (all P < 0.001). Positive LYI status was a factor of unfavorable 
prognosis also in patients without regional lymph node metastases.
Conclusions. Our results support earlier observations that LYI is a powerful prognostic factor. We recommend 
an assessment of LYI status during routine review of cutaneous melanoma slides stained with H&E as a stand-
ard, potentially informative, yet economically beneficial procedure. (Folia Histochemica et Cytobiologica 2016, 
Vol. 54, No. 3, 126–133)
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Introduction
Lymphatic dissemination is a critical step in the 
natural history of melanoma. The presence of nodal 
metastases is one of the most crucial determinants of 
patient’s prognosis that greatly influences the thera-
peutic approach [1]. Although the patients with no 
evidence of nodal involvement generally have a better 
prognosis than those in metastatic stage of the disease, 
the N0 group remains very heterogeneous with respect 
to survival [2]. It motivates researchers to continue 
to seek novel prognostic factors which would further 
stratify these patients and help delineate a group that 
could benefit from more aggressive treatment and 
intensified follow-up.
One of the parameters potentially useful for risk 
stratification is lymphatic invasion (LYI). Its pro-
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gnostic significance was postulated, although not 
always unanimously, in melanoma [3–7] and multiple 
other cancer types, e.g. lung [8], breast [9, 10], cervical 
[11, 12], ovarian [13], gastric [14], colorectal [15, 16], 
prostate [17] or bladder [18] cancers. Invasion of 
lymphatic vasculature within the primary tumor 
occurs ahead of nodal involvement in the course of 
cancer dissemination [19]. Therefore, morphological 
determination of LYI offers the possibility to spot 
aggressive, but relatively early-stage melanomas in 
which no nodal foci of cancer are yet apparent, but 
invasive melanocytes had already entered lymphatic 
vessels — a situation placing these tumors somewhat 
on the line between localized and metastatic phase. 
Interestingly, several studies demonstrated the 
relationship between angiolymphatic invasion and 
positive sentinel lymph node biopsy (SLNB) status, 
an observation that may be helpful in the selection of 
patients for this procedure [6, 7, 20, 21].
Despite presumable prognostic significance of LYI 
status and a recommendation for its assessment in 
cutaneous melanoma by the American College of Pa-
thologists [22], it is frequently omitted in the final mela-
noma pathology report. Unfortunately, comprehensive 
and large-scale studies on LYI are still insufficient, 
therefore the actual value of this potentially powerful 
parameter in American Joint Committee on Cancer 
(AJCC) melanoma staging remains marginal [2].
The aim of the present study was to examine the 
relationship of LYI status in hematoxylin and eosin 
(H&E) stained melanoma primary tumor samples 
with patient survival and other clinicopathological and 
histopathological characteristics. Special attention 
was placed on the prognostic significance of LYI in 
lymph node-negative patients.
Material and methods
Patients. The study group consisted of 104 patients with cuta-
neous malignant melanoma diagnosed between 2005 and 2010 
and treated in the Lower Silesian Oncology Center in Wro-
claw, Poland. The group was selected on the basis of the avail-
ability of tissue material (paraffin blocks and H&E-stained 
slides) and medical documentation. Comprehensive clinical 
data were obtained from archival medical records. The diag-
nostic and therapeutic procedures were determined on the 
basis of medical records of the Oncology Outpatient Clinic 
of the Lower Silesian Oncology Center and data provided by 
the Lower Silesian Cancer Registry and Civil Register Office 
(Wroclaw, Poland). The study was approved by the Ethical 
Committee of the Wroclaw Medical University, Poland. 
The clinicopathological profile of patients included the 
following parameters: age and gender, primary tumor loca-
tion, tumor stratification according to AJCC (pT), presence or 
absence of nodal (pN) and distant (pM) metastases, informa-
tion on disease recurrence and SLNB procedures (Table 1).
Tumor samples and histopathological evaluation. Tumor 
specimens were fixed in 10% buffered formalin and embed-
ded in paraffin. All H&E stained sections were examined 
by two pathologists. The parameters of the primary tumor 
recorded in pathology reports were Breslow thickness, Clark 
level, growth phase, histologic type, mitotic rate (number 
of mitotic figures per 1 mm2), presence of ulceration, lym-
phangioinvasion, microsatellitosis, intensity of lymphocytic 
inflammatory infiltrate (TILs, tumor-infiltrating lympho-
cytes) and microscopic evidence of regression (Table 2). 
Statistical analysis. Statistical analysis was performed using 
the Statistica 10.0 (Statsoft, Tulsa, OK, USA) and IBM SPSS 
21 (IBM, Armonk, NY, USA) software packages. Overall 
survival (OS) was defined as the time between the primary 
surgical treatment and death, and OS was censored at the last 
follow-up of patients who were still alive. Disease-free survival 
(DFS) was defined as the time between the primary surgical 
treatment and the date of relapse. DFS was censored at the last 
follow-up of patients who survived without disease recurrence 
or at the date of non-cancer associated death. Cancer-specific 
overall survival (CSOS) was defined as the time between the 
primary surgical treatment and cancer-associated death, and 
was censored at the last follow-up of surviving patients. 
A c2 test, exact Fisher test in the case of 2 × 2 tables, and 
Spearman rank correlation were used to analyze associations 
between mitotic rate and the presence of ulceration and clin-
icopathological parameters. Differences between the means 
were tested with a nonparametric test (Mann-Whitney U 
test and Kruskal-Wallis test). The log-rank test was used to 
compare survival in two groups, and the overall survival rate 
was estimated by the Kaplan-Meier method. The influence 
of explanatory variables on death risk was analyzed by means 
of the Cox proportional hazard regression. P values < 0.05 
were considered statistically significant.
Results
The frequency of lymphatic invasion  
in 104 melanoma patients
The presence of LYI was observed in 30 (28.8%) pa-
tients (Figure 1). With regard to regional lymph node 
status, LYI was detected in 15 out of 86 pN-negative 
patients, whereas 15 out of 18 patients in the pN-pos-
itive group had observable LYI (Table 1).
Correlations between lymphatic invasion  
and clinicopathological parameters
The presence of lymphatic invasion significantly 
correlated with higher regional advancement of the 
primary tumor (pT; P < 0.001). Moreover, it was 
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observed more often in patients with positive SLNB 
status (P < 0.001). Furthermore, the presence of LYI 
was associated with the presence of regional lymph 
node (pN; P < 0.001) and distant metastases (pM; 
P = 0.002). Importantly, the disease recurred more 
frequently in patients with detected LYI (P < 0.001). 
No statistically significant relationships between LYI 
and age at the moment of diagnosis, gender or primary 
tumor location were observed (Table 1).
Correlations between lymphatic invasion  
and histopathological parameters
Higher tumor advancement according to Breslow 
thickness and Clark level was associated with the 
presence of LYI (P < 0.001 in both cases). Moreover, 
LYI-positive tumors were more frequently ulcerated 
(P < 0.001) and presented higher levels of mitotic rate 
(P < 0.001). Interestingly, LYI was observed more 
often in melanomas of nodular and acral-lentiginous 
histologic types (P = 0.037). No significant correlations 
were observed between LYI and other histopathologi-
cal characteristics: TIL grade, growth phase, microsat-
ellitosis and tumor regression (Table 2).
Impact of lymphatic invasion status  
on 5-year survival of melanoma patients
Kaplan-Meier analysis revealed that the presence 
of lymphatic invasion significantly correlated with 
Table 1. Clinicopathological characteristics of the patients with or without lymphangioinvasion (LYI)
Clinicopathological characteristics No (%) Absence of LYI Presence of LYI P value
All patients 104 (100.0) 74 (71.2) 30 (28.8)
Age in years 
(range 21–79; median 58.5 y) 56.5 ± 15.4a 0.411b
Genderc
Female 60 (57.7) 43 17 0.532
Male 44 (42.3) 31 13
Primary tumor locationd
Head/neck  15 (14.4) 10 5
Extremities 45 (43.3) 34 11 0.777
Hand/foot 2 (1.9) 1 1
Trunk 42 (40.4) 29 13
Primary tumor (pT)b
pT1 34 (32.7) 33 1
pT2 21 (20.2) 18 3 < 0.0001
pT3 26 (25.0) 12 14
pT4 23 (22.1) 11 12
Sentinel lymph node biopsy status (SNLB)c 60 (57.7)
No metastases (SNLB–) 48 (80.0) 44 4 < 0.0001
Metastases present (SNLB+) 12 (20.0) 3 9
Regional lymph nodes status (pN)c
No metastases (pN–) 86 (82.7) 71 15 < 0.0001
Metastases present (pN+) 18 (17.3) 3 15
Recurrencec
No 87 (83.7) 69 18 < 0.0001
Yes 17 (16.3) 5 12
Distant metastasesc
No 99 (95.2) 74 25 0.002
Yes 5 (4.8) 0 5
aMean ± SD; bP value of Mann-Whitney’s U test; cP value of Fisher’s exact test; dP value of c2 test. Statistically significant differences are shown in 
bold font (P < 0.05).
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shorter overall survival (OS, Figure 2A, P < 0.001), 
cancer-specific overall survival (CSOS, Figure 2B, 
P < 0.001) and disease-free survival (DFS, Figure 2C, 
P < 0.001). Another survival analysis was performed 
in a subgroup of patients without regional lymph-
node metastases. Positive LYI status was found to be 
a factor of unfavorable prognosis defined as shorter OS 
(P = 0.001, Figure 2D), CSOS (P < 0.001, Figure 2E) 
and DFS (P < 0.001, Figure 2F).
Discussion
Lymphatic spread is a crucial mechanism of melanoma 
dissemination, and LYI along with lymphangiogenesis 
Table 2. Correlations between lymphangioinvasion and histopathological characteristics of primary tumors
Histopathological parameters No (%) Lack of LYI Presence of LYI P value
Breslow thicknessa
< 0.001
£ 1 mm 34 (32.7) 33 1
1.01–2.00 mm 20 (19.2) 17 3
2.01–4.00 mm 27 (26.0) 13 14
> 4 mm 23 (22.1) 11 12
Clark thicknessa
< 0.001
I 0 (0.0)
II 18 (17.3) 18 0
III 49 (47.1) 37 12
IV 26 (25.0) 16 10
V 11 (10.6) 3 8
Histologic typeb
0.037
Superficial spreading melanoma (SSM) 68 (65.4) 54 14
Nodular malignant melanoma (NMM) 32 (30.8) 18 14
Acral-lentiginous melanoma (ALM) 4 (3.8) 2 2
Mitotic ratea
< 0.001
0 45 (43.3) 43 2
1–2 26 (25.0) 20 6
≥ 3 33 (31.7) 11 22
Ulcerationc
< 0.001No 55 (52.9) 49 6
Yes 49 (47.1) 25 24
TILsc
0.065No and non-brisk 52 (50.0) 33 19
Brisk 52 (50.0) 41 11
Growth phasec
0.356Radial 3 (2.9) 3 0
Vertical 101 (97.1) 71 30
Microsatellitosisc
0.056No 98 (94.2) 72 26
Yes 6 (5.8) 2 4
Tumor regressionc 
0.581No 96 (92.3) 68 28
Yes 8 (7.7) 6 2
aP value of Mann-Whitney’s U test; bP value of c2 test; cP value of Fisher’s exact test. Statistically significant results (P < 0.05) are shown in bold 
font.
130 Piotr Donizy et al.
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2016
10.5603/FHC.a2016.0016
www.fhc.viamedica.pl
Figure 1. Lymphatic invasion in hematoxylin-eosin stained sections of melanoma patients. A. Tumor thrombus in a thin-
-walled lymphatic vessel (×600); B. Nest of melanoma cells in the lymphatic vessel with abundant melanin in the cancer 
cell cytoplasm (×400); C. Massive invasion in the lymphatic vessel with vast destruction of the wall and breakdown of lym-
phatic endothelium (×600); D and E. Tumor thrombi within deep lymphatic vessels in the dermis (×400); F. Advanced  
cutaneous melanoma (Breslow thickness 4.2 mm, Clark V) with distinct lymphangioinvasion. Abundant melanin in the 
tumor infiltration and melanoma cells located in the thin-walled lymphatic vessels (×200).
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Figure 2. Prognostic significance of lymphatic invasion (LYI) status for 5-year survival of melanoma patients. Presence of 
LYI was strongly related to unfavorable prognosis defined as shorter overall survival (A), cancer-specific overall survival 
(B) and disease free survival (C) in the entire study group. Moreover, also in lymph node-negative patients positive LYI 
status was a factor indicating poor outcome; D — overall survival; E — cancer-specific overall survival; F — disease free 
survival (DFS).
A D
B E
C F
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in the primary tumor are important phenomena in 
the course of events leading to metastasis [23, 24]. 
In our study, we demonstrated several correlations 
between LYI status and other histopathological and 
clinicopathological features in cutaneous melanoma 
patients. LYI was observed more frequently in tumors 
with deeper infiltration according to Breslow and 
Clark, and in tumors with ulceration and high MR. 
Moreover, LYI correlated with the presence of SLN, 
regional and distant metastases as well as the disease 
recurrence. 
Although definitive collective conclusions have 
yet not been drawn and considerable differences exist 
between various studies, a number of groups present-
ed statistically significant associations between LYI 
status and key melanoma characteristics such as tumor 
thickness [3, 25, 26], ulceration [3, 25, 26], MR [25, 26], 
or SLN [6, 7, 20, 27]. The observed correlations give 
good reasons for further exploring LYI as a parameter 
of potential practical application. Furthermore, our 
results indicate that positive LYI status is related to 
poor outcome defined as shorter CSOS, DFS, as well 
as OS. Prognostic significance of LYI in the context 
of patient survival was demonstrated by several labo-
ratories [3, 6, 28], while other groups did not confirm 
this observation [7, 26, 29].
Importantly, positive LYI status was strongly cor-
related with shorter survival also in N0 subgroup of pa-
tients. This association was evident with regard to all 
considered endpoints: CSOS, DFS and OS. It is likely 
that the presence of neoplastic cells within lymphatic 
vasculature of the primary tumor is a manifestation of 
their aggressive phenotype and ability to metastasize. 
However, it has to be considered that some patients 
develop metastasis without evidence of LYI in the 
primary tumor, and conversely — LYI may be present 
with no indication of concurrent metastatic spread. 
Considering this inconsistency, in lymph node-nega-
tive patients, LYI-positivity may shortly precede the 
metastatic spread, or even be associated with already 
existent submicroscopic micrometastases, detectable 
solely by reverse transcriptase-polymerase chain 
reaction assay [30, 31]. What might result from this 
pitfall are more aggressive therapies which should 
be performed in LYI(+) patients. In our study, the 
recurrence rate within LYI-positive N0 patients was 
extraordinarily high (11 of 15; 73.3%; data not shown). 
The study of Borgstein et al. revealed that evidence 
of LYI in the primary tumor significantly correlated 
with locoregional cutaneous recurrence [32]. Among 
clinical stage I patients, 93% of LYI-positive subjects 
developed in-transit metastases compared with 1.6% 
in LYI-negative group [32]. Vuylsteke et al. demon-
strated in a group of 209 clinical stage I/II patients 
after SLN dissection, that LYI was a strong predictor 
of DFS and OS both in univariate and multivariate 
analysis [33]. Interestingly, LYI was the strongest 
predictor in a multivariable model of DFS analysis, 
followed by ulceration, SLN status and Breslow thick-
ness [33]. In the case of OS, LYI was superior to SLN 
status and Breslow thickness, whereas ulceration was 
found non-significant [33]. 
Many of the above cited studies used immunohis-
tochemical markers for blood and/or lymphatic vas-
culature like D2-40, LYVE-1, CD31 or CD34. With 
the advent of modern biotechnology, such methods 
have become increasingly popular for scientific and 
diagnostic purposes. Nevertheless, classical H&E 
staining remains the standard diagnostic technique 
available for every pathologist. An important outcome 
of our results is that LYI assessment may be beneficial 
even with this simple tool.
In conclusion, we demonstrated that positive LYI 
status was related to poor outcome defined as shorter 
CSOS, DFS and OS in the whole study population and 
in lymph node-negative patients. We recommend an 
assessment of LYI status to be done during routine 
review of H&E slides of cutaneous melanoma as 
a standard, potentially informative, yet economically 
beneficial procedure. Comprehensive and large-scale 
studies should follow this preliminary report to estab-
lish LYI status as a stratification criterion in future 
editions of AJCC staging system.
Acknowledgements
This study was supported by Wroclaw Medical Uni-
versity research grant ST.B130.16.049.
Conflict of interest
The authors declare that there is no conflict of in-
terest.
References
1. Fox MC, Lao CD, Schwartz JL, Frohm ML, Bichakjian CK, 
Johnson TM. Management options for metastatic mel-
anoma in the era of novel therapies: a primer for the 
practicing dermatologist. Part I: Management of stage III 
disease. J Am Acad Dermatol. 2013;68:e1–e9. doi: 10.1016/j.
jaad.2012.09.040.
2. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 
2009 AJCC melanoma staging and classification. J Clin Oncol. 
2009;27:6199–6206. doi: 10.1200/JCO.2009.23.4799.
3. Kashani-Sabet M, Sagebiel RW, Ferreira CM, Nosrati M, 
Miller JR 3rd. Vascular involvement in the prognosis of 
primary cutaneous melanoma. Arch Dermatol. 2001;137:1169–
–1173. doi: 10.1001/archderm.137.9.1169.
4. Zettersten E, Sagebiel RW, Miller JR 3rd, Tallapureddy S, 
Leong SP, Kashani-Sabet M. Prognostic factors in pa-
133Lymphangioinvasion in cutaneous melanoma
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2016
10.5603/FHC.a2016.0016
www.fhc.viamedica.pl
tients with thick cutaneous melanoma (> 4 mm). Cancer. 
2002;94:1049–1056. doi: 10.1002/cncr.10326.
5. Nagore E, Oliver V, Botella-Estrada R, Moreno-Picot S, Insa A, 
Fortea JM. Prognostic factors in localized invasive cutaneous 
melanoma: high value of mitotic rate, vascular invasion and 
microscopic satellitosis. Melanoma Res. 2005;15:169–177. doi: 
10.1097/00008390-200506000-00005.
6. Petersson F, Diwan AH, Ivan D et al. Immunohistochemical 
detection of lymphovascular invasion with D2-40 in melanoma 
correlates with sentinel lymph node status, metastasis and sur-
vival. J Cutan Pathol. 2009;36:1157–1163. doi: 10.1111/j.1600-
0560.2008.01242.x.
7. Doeden K, Ma Z, Narasimhan B, Swetter SM, Detmar M, 
Dadras SS. Lymphatic invasion in cutaneous melanoma is as-
sociated with sentinel lymph node metastasis. J Cutan Pathol. 
2009;36:772–780. doi: 10.1111/j.1600-0560.2008.01166.x.
8. Higgins KA, Chino JP, Ready N et al. Lymphovascular in-
vasion in non-small-cell lung cancer: implications for staging 
and adjuvant therapy. J Thorac Oncol. 2012;7:1141–1147. doi: 
10.1097/JTO.0b013e3182519a42.
9. Truong PT, Yong CM, Abnousi F et al. Lymphovascular 
invasion is associated with reduced locoregional control and 
survival in women with node-negative breast cancer treated 
with mastectomy and systemic therapy. J Am Coll Surg. 
2005;200:912–921. doi: 10.1016/j.jamcollsurg.2005.02.010.
10. Ejlertsen B, Jensen MB, Rank F et al. Population-based 
study of peritumoral lymphovascular invasion and outcome 
among patients with operable breast cancer. J Natl Cancer 
Inst. 2009;101:729–735. doi: 10.1093/jnci/djp090.
11. Takeda N, Sakuragi N, Takeda M et al. Multivariate analysis 
of histopathologic prognostic factors for invasive cervical 
cancer treated with radical hysterectomy and systematic ret-
roperitoneal lymphadenectomy. Acta Obstet Gynecol Scand. 
2002;81:1144–1151. doi: 10.1034/j.1600-0412.2002.811208.x.
12. Creasman WT, Kohler MF. Is lymph vascular space involve-
ment an independent prognostic factor in early cervical 
cancer? Gynecol Oncol. 2004;92:525–529. doi: 10.1016/j.
ygyno.2003.11.020.
13. Matsuo K, Yoshino K, Hasegawa K et al. Survival outcome 
of stage I ovarian clear cell carcinoma with lympho-vascu-
lar space invasion. Gynecol Oncol. 2015;136:198–204. doi: 
10.1016/j.ygyno.2014.12.006.
14. Setala LP, Kosma VM, Marin S et al. Prognostic factors in 
gastric cancer: the value of vascular invasion, mitotic rate and 
lymphoplasmacytic infiltration. Br J Cancer. 1996;74:766–772. 
doi: 10.1038/bjc.1996.434.
15. Betge J, Pollheimer MJ, Lindtner RA et al. Intramural and 
extramural vascular invasion in colorectal cancer: prognos-
tic significance and quality of pathology reporting. Cancer. 
2012;118:628–638. doi: 10.1002/cncr.26310.
16. Akagi Y, Adachi Y, Ohchi T, Kinugasa T, Shirouzu K. 
Prognostic impact of lymphatic invasion of colorectal cancer: 
a single-center analysis of 1,616 patients over 24 years. Anti-
cancer Res. 2013;33:2965–2970.
17. Cheng L, Jones TD, Lin H et al. Lymphovascular invasion 
is an independent prognostic factor in prostatic adeno-
carcinoma. J Urol. 2005;174:2181–2185. doi: 10.1097/01.
ju.0000181215.41607.c3.
18. Cheng L, Montironi R, Davidson DD, Lopez-Beltran A. 
Staging and reporting of urothelial carcinoma of the urinary 
bladder. Mod Pathol. 2009;22(Suppl 2):S70–S95. doi: 10.1038/
modpathol.2009.1.
19.  Cao Y. Opinion: emerging mechanisms of tumour lymph-
angiogenesis and lymphatic metastasis. Nat Rev Cancer. 
2005;5:735–743. doi: 10.1038/nrc1693.
20. Mraz-Gernhard S, Sagebiel RW, Kashani-Sabet M, Miller JR 
3rd, Leong SP. Prediction of sentinel lymph node micrometas-
tasis by histological features in primary cutaneous malignant 
melanoma. Arch Dermatol. 1998;134:983–987. doi: 10.1001/
archderm.134.8.983. 
21. Nguyen CL, McClay EF, Cole DJ et al. Melanoma thickness 
and histology predict sentinel lymph node status. Am J Surg. 
2001;181:8–11. doi: 10.1016/s0002-9610(00)00533-x.
22. Frishberg DP, Balch C, Balzer BL et al. Protocol for the 
examination of specimens from patients with melanoma of 
the skin. Arch Pathol Lab Med. 2009;133:1560–1567. doi: 
10.1043/1543-2165-133.10.1560.
23. Dadras SS, Paul T, Bertoncini J et al. Tumor lymphangiogen-
esis: a novel prognostic indicator for cutaneous melanoma 
metastasis and survival. Am J Pathol. 2003;162:1951–1960. 
doi: 10.1016/S0002-9440(10)64328-3.
24. Alitalo A, Detmar M. Interaction of tumor cells and lymphatic 
vessels in cancer progression. Oncogene. 2012;31:4499–4508. 
doi: 10.1038/onc.2011.602.
25. Xu X, Chen L, Guerry D et al. Lymphatic invasion is inde-
pendently prognostic of metastasis in primary cutaneous mel-
anoma. Clin Cancer Res. 2012;18:229–237. doi: 10.1158/1078-
0432.CCR-11-0490.
26. Storr SJ, Safuan S, Mitra A et al. Objective assessment of 
blood and lymphatic vessel invasion and association with 
macrophage infiltration in cutaneous melanoma. Mod Pathol. 
2012;25:493–504. doi: 10.1038/modpathol.2011.182.
27. Niakosari F, Kahn HJ, McCready D et al. Lymphatic invasion 
identified by monoclonal antibody D2-40, younger age, and 
ulceration: predictors of sentinel lymph node involvement in 
primary cutaneous melanoma. Arch Dermatol. 2008;144:462–
–467. doi: 10.1001/archderm.144.4.462.
28. Xu X, Gimotty PA, Guerry D et al. Lymphatic invasion 
revealed by multispectral imaging is common in primary 
melanomas and associates with prognosis. Hum Pathol. 
2008;39:901–909. doi: 10.1016/j.humpath.2007.10.017.
29. Petitt M, Allison A, Shimoni T, Uchida T, Raimer S, Kelly B. 
Lymphatic invasion detected by D2-40/S-100 dual immuno-
histochemistry does not predict sentinel lymph node status 
in melanoma. J Am Acad Dermatol. 2009;61:819–828. doi: 
10.1016/j.jaad.2009.04.026.
30. Blaheta HJ, Ellwanger U, Schittek B et al. Examination of 
regional lymph nodes by sentinel node biopsy and molecular 
analysis provides new staging facilities in primary cutane-
ous melanoma. J Invest Dermatol. 2000;114:637–642. doi: 
10.1046/j.1523-1747.2000.00925.x.
31. Bostick PJ, Morton DL, Turner RR et al. Prognostic sig-
nificance of occult metastases detected by sentinel lymph-
adenectomy and reverse transcriptase-polymerase chain 
reaction in early-stage melanoma patients. J Clin Oncol. 
1999;17:3238–3244.
32. Borgstein PJ, Meijer S, van Diest PJ. Are locoregional cuta-
neous metastases in melanoma predictable? Ann Surg Oncol. 
1999;6:315–321. doi: 10.1007/s10434-999-0315-x. 
33. Vuylsteke RJ, van Leeuwen PA, Statius Muller MG, Gietema HA, 
Kragt DR, Meijer S. Clinical outcome of stage I/II melanoma 
patients after selective sentinel lymph node dissection: long-
term follow-up results. J Clin Oncol. 2003;21:1057–1065. doi: 
10.1200/jco.2003.07.170. 
Submitted: 16 March, 2016 
Accepted after reviews: 2 August, 2016 
Available as AoP: 16 August, 2016
